Lecanemab (Leqembi): The First Drug to Slow Alzheimer's Decline

Lecanemab (brand name Leqembi) is a monoclonal antibody developed by Eisai and Biogen that targets amyloid-beta, a protein that accumulates abnormally in the brains of people with Alzheimer's disease. Specifically, lecanemab binds to soluble protofibrils — intermediate forms of amyloid that are thought to be particularly toxic to neurons — and to amyloid plaques already deposited in brain tissue.

The drug is administered intravenously every two weeks. It works by recruiting the immune system to recognize and clear these amyloid aggregates. Clinical trials demonstrated that lecanemab reduces amyloid burden on PET scans substantially — effectively clearing much of the accumulated amyloid from affected brain regions over 18 months.

Lecanemab belongs to a class of treatments called anti-amyloid immunotherapies. Earlier drugs in this class — aducanumab, gantenerumab — also cleared amyloid but failed to demonstrate corresponding clinical benefit in large trials. Lecanemab is the first in this class to show a statistically significant and clinically meaningful slowing of cognitive and functional decline.

The pivotal evidence for lecanemab comes from the CLARITY AD trial, published in the New England Journal of Medicine in January 2023. The trial enrolled 1,795 people with early Alzheimer's disease — specifically, those with confirmed amyloid pathology and either mild cognitive impairment or mild dementia due to Alzheimer's. Participants were randomized to receive lecanemab or placebo for 18 months.

The primary outcome was change on the CDR-SB (Clinical Dementia Rating Sum of Boxes), a scale measuring both cognitive and functional status. People receiving lecanemab declined 27% more slowly than those receiving placebo — a statistically significant result. Secondary outcomes including measures of cognition, function, and quality of life also favored lecanemab.

The FDA granted full approval in July 2023 based on this data, making lecanemab the first disease-modifying Alzheimer's treatment to receive traditional (non-accelerated) FDA approval on the basis of clinical outcomes, not just biomarker change.

Lecanemab comes with a significant side effect: amyloid-related imaging abnormalities (ARIA), which include brain swelling (ARIA-E) and microhemorrhages (ARIA-H). In the CLARITY AD trial, about 21% of participants developed ARIA-E, and 9% developed symptomatic ARIA. Three deaths potentially related to ARIA occurred in the broader lecanemab program, raising important safety questions that require careful patient selection and monitoring.

Lecanemab is specifically indicated for people with early Alzheimer's disease — those with confirmed amyloid pathology (demonstrated by PET scan or cerebrospinal fluid testing) and mild cognitive impairment or mild dementia. It is not indicated for people without confirmed amyloid pathology, for people in later stages of Alzheimer's, or for people with other forms of dementia.

This narrow indication reflects an important reality: the earlier in the disease process treatment begins, the better the prospects. By the time someone has moderate or advanced Alzheimer's, the neurodegenerative damage is extensive enough that clearing amyloid may not restore function. Lecanemab reinforces the importance of early detection.

The treatment requires every-two-week infusions, amyloid confirmation before starting, and MRI monitoring for ARIA throughout treatment. It also requires anticoagulant medication review, as ARIA risk is elevated in people on blood thinners. The practical and logistical burden is significant. APOE4 carriers face higher ARIA risk and require careful counseling before starting.

For people not yet in the early Alzheimer's stage but concerned about their cognitive trajectory, the message from lecanemab research is that earlier identification is clinically meaningful. This is a drug that only works when started early — which means detection tools that identify decline at the earliest possible stage have real clinical relevance.

Lecanemab represents a genuine milestone: the first drug to demonstrate that intervening in amyloid pathology translates into slower clinical decline. This validates the amyloid hypothesis at a basic level, even though it does not mean amyloid is the whole story of Alzheimer's pathogenesis.

The 27% slowing in the CLARITY AD trial is meaningful but modest. Patients and families considering the treatment need realistic expectations: the drug slows decline, it does not stop it, and it does not restore lost function. The absolute magnitude of benefit, while statistically significant, is clinically modest for an individual patient.

The field is now focused on two parallel questions: Can better patient selection (earlier intervention, genetic stratification) improve outcomes? And can combination approaches — pairing amyloid clearance with anti-tau therapies, neuroprotective strategies, or lifestyle interventions — amplify the benefit?

Lecanemab also changes the economics of early diagnosis. If an effective early treatment exists, the value of detecting Alzheimer's before symptoms are severe rises enormously. This is driving investment in blood-based biomarkers, digital detection tools, and monitoring approaches that can identify at-risk individuals earlier and more cost-effectively than PET scanning.